title: Effect of two dietary fibers on satiety and glycemic parameters: a randomized, double-blind, placebo-controlled, exploratory study.
abstract: BACKGROUND
  Dietary carbohydrates may affect metabolic and physiologic parameters. The present study evaluated whether a combination of two dietary fibers, oligofructose (OFS) and pectin (P), altered satiety and glycemic parameters. The primary objective of this study was to determine whether dietary supplementation for 3 weeks with OFS + P would produce a greater reduction in energy intake of an ad libitum test meal compared to control.
  
  
  METHODS
  This was a single center, randomized, double-blind, placebo-controlled, parallel group study in overweight and obese, otherwise healthy, subjects (N = 96). There were two OFS + P treatment groups: high-dose (30 g/d), low-dose (15 g/d), and a control group (maltodextrin 15 g/d). Energy intake, appetite measures based on Satiety Labeled Intensity Magnitude (SLIM) scale, fasting and post-prandial glucose, and insulin levels and body weight were measured at baseline and at the end of 3 weeks. Adverse events and gastrointestinal tolerability of the treatments were also assessed.
  
  
  RESULTS
  An analysis of covariance (ANCOVA) performed on the primary endpoint change from baseline in energy intake, showed no statistically significant difference in energy intake among the three treatment groups (p = 0.5387). The LS mean changes (SE) in energy intake from baseline to week 3 were -58.3 (42.4) kilocalories (kcal) for the high dose group, -74.2 (43.6) kcal for the low dose group, and -9.0 (42.9) kcal for the control group. For the pairwise comparisons of OFS + P doses and control, confidence intervals were constructed around the difference in LS mean changes. All study products were generally well tolerated.
  
  
  CONCLUSIONS
  There was a directional benefit in ad libitum energy intake for both OFS + P doses compared to control, with a greater reduction in kilocalories in the low dose comparison, but the reductions were not significant. Further studies are warranted.
  
  
  BACKGROUND
  GSK Clinical Study Register # W7781293.
authors.forename: David M
authors.initials: DM
authors.lastname: Savastano
authors.affiliation: Discovery Medicine, GlaxoSmithKline, Five Moore Drive, MS N2-3208, Research Triangle Park, NC 27709, USA. rebecca.j.hodge@gsk.com.
authors.forename: Rebecca J
authors.initials: RJ
authors.lastname: Hodge
authors.forename: Derek J
authors.initials: DJ
authors.lastname: Nunez
authors.forename: Ann
authors.initials: A
authors.lastname: Walker
authors.forename: Roxanne
authors.initials: R
authors.lastname: Kapikian
mesh_terms: D000328:Adult; D001066:Appetite / Q000187:drug effects; D001786:Blood Glucose / Q000187:drug effects*; D004043:Dietary Fiber / Q000008:administration & dosage* / Q000494:pharmacology; D004311:Double-Blind Method; D002149:Energy Intake / Q000187:drug effects; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000188:drug therapy; D009844:Oligosaccharides / Q000008:administration & dosage* / Q000494:pharmacology; D050177:Overweight; D010368:Pectins / Q000008:administration & dosage* / Q000494:pharmacology; D012527:Satiation
chemical_list: D001786:Blood Glucose; D004043:Dietary Fiber; D009844:Oligosaccharides; C120489:oligofructose; D010368:Pectins